|
1
|
Raggatt LJ and Partridge NC: Cellular and
molecular mechanisms of bone remodeling. J Biol Chem.
285:25103–25108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weitzmann MN and Pacifici R: Estrogen
deficiency and bone loss: An inflammatory tale. J Clin Invest.
116:1186–1194. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnell O and Kanis JA: An estimate of the
worldwide prevalence and disability associated with osteoporotic
fractures. Osteoporos Int. 17:1726–1733. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boyce BF, Yoneda T and Guise TA: Factors
regulating the growth of metastatic cancer in bone. Endocr Relat
Cancer. 6:333–347. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mundy GR: Metastasis to bone: Causes,
consequences and therapeutic opportunities. Nat Rev Cancer.
2:584–593. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roodman GD: Mechanism of bone metastasis.
N Engl J Med. 350:1655–1664. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Akhtari M, Mansuri J, Newman KA, Guise TM
and Seth P: Biology of breast cancer bone metastasis. Cancer Biol
Ther. 7:3–9. 2008. View Article : Google Scholar
|
|
8
|
Coleman RE: Metastatic bone disease:
Clinical features, pathophysiology and treatment strategies. Cancer
Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen YC, Sosnoski DM and Mastro AM: Breast
cancer metastasis to the bone: Mechanisms of bone loss. Breast
Cancer Res. 12:2152010. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park BK, Zhang H, Zeng Q, Dai J, Keller
ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S,
Chen S and Wang CY: NF-kappaB in breast cancer cells promotes
osteolytic bone metastasis by inducing osteoclastogenesis via
GM-CSF. Nat Med. 13:62–69. 2007. View
Article : Google Scholar
|
|
11
|
Gonzalez-Suarez E, Jacob AP, Jones J,
Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D and
Dougall WC: RANK ligand mediates progestin-induced mammary
epithelial proliferation and carcinogenesis. Nature. 468:103–107.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zaidi M, Blair HC, Moonga BS, Abe E and
Huang CL: Osteoclastogenesis, bone resorption, and osteoclast-based
therapeutics. J Bone Miner Res. 18:599–609. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weilbaecher KN, Guise TA and McCauley LK:
Cancer to bone: a fatal attraction. Nat Rev Cancer. 11:411–425.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berrios RL and Arbiser JL: Effectiveness
of gentian violet and similar products commonly used to treat
pyodermas. Dermatol Clin. 2011:69–73. 2011. View Article : Google Scholar
|
|
15
|
Perry BN, Govindarajan B, Bhandarkar SS,
Knaus UG, Valo M, Sturk C, Carrillo CO, Sohn A, Cerimele F, Dumont
D, et al: Pharmacologic blockade of angiopoietin-2 is efficacious
against model hemangiomas in mice. J Invest Dermatol.
126:2316–2322. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang X, Zheng Y, Fried LE, Du Y, Montano
SJ, Sohn A, Lefkove B, Holmgren L, Arbiser JL, Holmgren A, et al:
Disruption of the mitochondrial thioredoxin system as a cell death
mechanism of cationic triphenylmethanes. Free Radic Biol Med.
50:811–820. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamaguchi M, Vikulina T, Arbiser JL and
Weitzmann MN: Suppression of NF-κB activation by gentian violet
promotes osteoblastogenesis and suppresses osteoclastogenesis. Curr
Mol Med. 14:783–792. 2014. View Article : Google Scholar
|
|
18
|
Yamaguchi M, Zhu S, Weitzmann MN, Snyder
JP and Shoji M: Curcumin analog UBS109 prevents bone marrow
osteoblastogenesis and osteoclastogenesis disordered by coculture
with breast cancer MDA-MB-231 bone metastatic cells in vitro. Mol
Cell Biochem. 401:1–10. 2015. View Article : Google Scholar
|
|
19
|
Yoneda T, Williams PJ, Hiraga T, Niewolna
M and Nishimura R: A bone-seeking clone exhibits different
biological properties from the MDA-MB-231 parental human breast
cancer cells and a brain-seeking clone in vivo and in vitro. J Bone
Miner Res. 16:1486–1495. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Misawa H, Inagaki S and Yamaguchi M:
Suppression of cell proliferation and deoxyribonucleic acid
synthesis in the cloned rat hepatoma H4-II-E cells overexpressing
regucalcin. J Cell Biochem. 84:143–149. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamaguchi M and Daimon Y: Overexpression
of regucalcin suppresses cell proliferation in cloned rat hepatoma
H4-II-E cells: involvement of intracellular signaling factors and
cell cycle-related genes. J Cell Biochem. 95:1169–1177. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Izumi T and Yamaguchi M: Overexpression of
regucalcin suppresses cell death in cloned rat hepatoma H4-II-E
cells induced by tumor necrosis factor-alpha or thapsigargin. J
Cell Biochem. 92:296–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Minkin C: Bone acid phosphatase:
Tartrate-resistant acid phosphatase as a marker osteoclast
function. Calcif Tissue Int. 34:285–290. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamaguchi M, Zhu S, Zhang S, Wu D, Moore
TM, Snyder JP and Shoji M: Curcumin analogue UBS109 prevents bone
loss in breast cancer bone metastasis mouse model: Involvement in
osteoblastogenesis and osteoclastogenesis. Cell Tissue Res.
357:245–252. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Y, Li A, Strait K, Zhang H, Nanes MS
and Weitzmann MN: Endogenous TNFalpha lowers maximum peak bone mass
and inhibits osteoblastic Smad activation through NF-kappaB. J Bone
Miner Res. 22:646–655. 2007. View Article : Google Scholar : PubMed/NCBI
|
